A Toxic RNA Catalyzes the Cellular Synthesis of Its Own Inhibitor, Shunting It to Endogenous Decay Pathways
Raphael I. BenhamouiD, Alicia J. Angelbello, Eric T. WangiD, Matthew David DisneyiD
Abstract
Myotonic dystrophy type 2 (DM2) is a genetically defined muscular dystrophy caused by a toxic expanded repeat of r(CCUG) [heretofore (CCUG)exp], harbored in intron 1 of CHC-Type Zinc Finger Nucleic Acid Binding Protein (CNBP) pre-mRNA. This r(CCUG)exp causes DM2 via a gain-of-function mechanism that results in three hallmarks of its pathology: (i) binding to RNA-binding proteins (RBPs) that aggregate into nuclear foci; (ii) sequestration of muscleblind-like-1 (MBNL1) protein, a regulator of alternative pre-mRNA splicing, leading to splicing defects; and (iii) retention of intron 1 in the CNBP mRNA. Here, we find that CNBP intron retention is caused by the r(CCUG)exp-MBNL1 complex and can be rescued by small molecules. We studied two types of small molecules with different modes of action, ones that simply bind and ones that can be synthesized by a r(CCUG)exp-templated reaction in cells, that is the RNA synthesizes its own drug. Indeed, our studies completed in DM2 patient-derived fibroblasts show that the compounds disrupt the r(CCUG)exp-MBNL1 complex, reduce intron retention, subjecting the liberated intronic r(CCUG)exp to native decay pathways, and rescue other DM2-associated cellular defects. Collectively, this study shows that small molecules can affect RNA biology by shunting toxic transcripts towards native decay pathways.\n\nHIGHLIGHTSO_LIIntron retention in RNA repeat expansions can be due to repeats binding to proteins\nC_LIO_LISmall molecules that bind RNA repeats and inhibit protein binding can trigger decay\nC_LIO_LIA toxic RNA repeat can catalyze the synthesis of its own inhibitor on-site\nC_LIO_LIOn-site drug synthesis most potently affects disease biology\nC_LI\n\neTOC BLURBThe most common way to target RNA is to use antisense oligonucleotides to target unstructured RNAs for destruction. Here, we show for the first time that small molecules targeting structured, disease-causing RNAs can shunt them towards native decay pathways by affecting their processing.\n\n\n\nO_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=77 SRC=\"FIGDIR/small/741926v1_ufig1.gif\" ALT=\"Figure 1\">\nView larger version (21K):\norg.highwire.dtl.DTLVardef@1ff5d1forg.highwire.dtl.DTLVardef@3adccborg.highwire.dtl.DTLVardef@75caf0org.highwire.dtl.DTLVardef@15e58f4_HPS_FORMAT_FIGEXP M_FIG C_FIG
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 19
- FWCI
- 2.18
- Field percentile
- top 13%
- Organism
- Assay
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- A small molecule that binds an RNA repeat expansion stimulates its decay via the exosome complex
A. J. Angelbello, R. I. Benhamou, … M. D. Disney·bioRxiv·May 11, 2020
- A Minimal Synthetic Cleavage Module Enables Selective Degradation of Pathogenic r(CUG) Repeats in Cells
Jingsong Shan, Sandra Kovachka, … Matthew David Disney·bioRxiv·Nov 6, 2026
- A chemoinformatics-guided platform for efficient discovery of RNA-binding small molecules: Proof-of-concept for myotonic dystrophy type 1
Amirhossein Taghavi, Jingsong Shan, … Matthew David Disney·bioRxiv·May 13, 2026
- Quercetin selectively reduces expanded repeat RNA levels in models of myotonic dystrophy
Subodh Kumar Mishra, Sawyer M Hicks, … J. Andrew Berglund·NAR Molecular MedicinePeer-reviewed·Jan 1, 2026
- Regulation of Toxic RNA Foci and Repeat Expansion DMPK Transcripts: Role of MBNL Proteins and RNA Decay Pathways
Xiaomeng Xing, Róbert Márkus, … J. David Brook·bioRxiv·Sep 28, 2023
- NMR structures of small molecules bound to a model of an RNA CUG repeat expansion
Jonathan L. Chen, Amirhossein Taghavi, … Matthew David Disney·Bioorganic & Medicinal Chemistry LettersPeer-reviewed·Jun 22, 2024